C
CRISPR Therapeutics AG D
D
CRSP
36.820
USD
-0.79
(-2.10%)
مفتوح الان
حجم التداول
33,657
الربح لكل سهم
-5
العائد الربحي
-
P/E
-8
حجم السوق
3,179,910,845
الأخبار المقالات
العنوان: CRISPR Therapeutics AG
القطاع: Healthcare
الصناعة: Biotechnology
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.